These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8062327)

  • 1. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile.
    Davis GL; Balart LA; Schiff ER; Lindsay K; Bodenheimer HC; Perrillo RP; Carey W; Jacobson IM; Payne J; Dienstag JL
    Clin Ther; 1994; 16(2):334-43; discussion 271-2. PubMed ID: 8062327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health assessment for chronic HCV infection: results of quality of life.
    Carithers RL; Sugano D; Bayliss M
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):75S-80S. PubMed ID: 9011480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group.
    Poynard T; Bedossa P; Chevallier M; Mathurin P; Lemonnier C; Trepo C; Couzigou P; Payen JL; Sajus M; Costa JM
    N Engl J Med; 1995 Jun; 332(22):1457-62. PubMed ID: 7739681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group.
    Davis GL; Balart LA; Schiff ER; Lindsay K; Bodenheimer HC; Perrillo RP; Carey W; Jacobson IM; Payne J; Dienstag JL
    J Hepatol; 1990; 11 Suppl 1():S31-5. PubMed ID: 2127785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis D with interferon alfa-2a.
    Farci P; Mandas A; Coiana A; Lai ME; Desmet V; Van Eyken P; Gibo Y; Caruso L; Scaccabarozzi S; Criscuolo D
    N Engl J Med; 1994 Jan; 330(2):88-94. PubMed ID: 8259188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease.
    Volkmann J; Albanese A; Kulisevsky J; Tornqvist AL; Houeto JL; Pidoux B; Bonnet AM; Mendes A; Benabid AL; Fraix V; Van Blercom N; Xie J; Obeso J; Rodriguez-Oroz MC; Guridi J; Schnitzler A; Timmermann L; Gironell AA; Molet J; Pascual-Sedano B; Rehncrona S; Moro E; Lang AC; Lozano AM; Bentivoglio AR; Scerrati M; Contarino MF; Romito L; Janssens M; Agid Y
    Mov Disord; 2009 Jun; 24(8):1154-61. PubMed ID: 19412954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b.
    Saracco G; Rosina F; Abate ML; Chiandussi L; Gallo V; Cerutti E; Di Napoli A; Solinas A; Deplano A; Tocco A
    Hepatology; 1993 Dec; 18(6):1300-5. PubMed ID: 7694894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusion.
    Colombo M; Lampertico P; Rumi M
    Gut; 1993; 34(2 Suppl):S141. PubMed ID: 8314483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B hepatitis: interim results of a randomized controlled open study.
    Weiland O; Schvarcz R; Wejstål R; Norkrans G; Foberg U; Frydén A
    Scand J Infect Dis; 1989; 21(2):127-32. PubMed ID: 2499037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A comparative randomized controlled study of the efficacy of interferon alfa-2b and interferon alfa-2a in the treatment of chronic hepatitis C].
    Fernández I; Castellano G; Canga F; Colina F; García H; Fuertes A; Casis B; Martín A; Solís JA
    Gastroenterol Hepatol; 1995 Feb; 18(2):66-72. PubMed ID: 7621277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer history and other personal factors affect quality of life in patients with hepatitis C.
    Olson SH; Iyer S; Scott J; Erez O; Samuel S; Markovits T; Schwartz M; Toro C; Gambarin-Gelwan M; Kurtz RC
    Health Qual Life Outcomes; 2005 Jun; 3():39. PubMed ID: 15960844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Quality of life in patients with chronic obstructive lung diseases: psychometric criteria of the German version of the Sickness Impact Profile and initial results of its application].
    Hütter BO; Würtemberger G
    Pneumologie; 1997 Feb; 51(2):108-14. PubMed ID: 9157448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C.
    Fontana RJ; Moyer CA; Sonnad S; Lok ASF ; Sneed-Pee N; Walsh J; Klein S; Webster S
    Am J Gastroenterol; 2001 Jan; 96(1):170-8. PubMed ID: 11197249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus.
    Misiani R; Bellavita P; Fenili D; Vicari O; Marchesi D; Sironi PL; Zilio P; Vernocchi A; Massazza M; Vendramin G
    N Engl J Med; 1994 Mar; 330(11):751-6. PubMed ID: 8107741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial.
    Simon DM; Gordon SC; Kaplan MM; Koff RS; Regenstein F; Everson G; Lee YM; Weiner F; Silverman A; Plasse T; Fedorczyk D; Liao MJ
    Hepatology; 1997 Feb; 25(2):445-8. PubMed ID: 9021962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C.
    Lampertico P; Rumi M; Romeo R; Craxì A; Soffredini R; Biassoni D; Colombo M
    Hepatology; 1994 Jan; 19(1):19-22. PubMed ID: 7506225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
    Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
    Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.
    Boucher E; Jouanolle H; Andre P; Ruffault A; Guyader D; Moirand R; Turlin B; Jacquelinet C; Brissot P; Deugnier Y
    Hepatology; 1995 Feb; 21(2):322-7. PubMed ID: 7843700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The International development of PROQOL-HCV: An instrument to assess the health-related quality of life of patients treated for Hepatitis C virus.
    Armstrong AR; Herrmann SE; Chassany O; Lalanne C; Da Silva MH; Galano E; Carrieri PM; Estellon V; Sogni P; Duracinsky M
    BMC Infect Dis; 2016 Aug; 16(1):443. PubMed ID: 27553866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.